These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34083304)

  • 21. Is there any association between absolute lymphocyte count and increased tumor-infiltrating lymphocytes in metastatic sites in advanced breast cancer patients who get benefit from eribulin treatment?
    Altundag K
    Breast Cancer Res Treat; 2020 Jun; 181(3):691. PubMed ID: 32342232
    [No Abstract]   [Full Text] [Related]  

  • 22. Predictive value of peripheral blood markers in soft tissue sarcoma patients treated with eribulin.
    Ishihara S; Ogura K; Maejima A; Shimoi T; Sudo K; Kojima Y; Fukushima S; Osaki S; Kobayashi E; Iwata S; Matsui Y; Yonemori K; Kawai A
    Jpn J Clin Oncol; 2023 Jun; 53(6):494-500. PubMed ID: 36989466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic inflammation response index (SIRI) as a predictive factor for overall survival in advanced soft tissue sarcoma treated with eribulin.
    Kobayashi H; Okuma T; Okajima K; Ishibashi Y; Zhang L; Hirai T; Ohki T; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Goto T; Tanaka S
    J Orthop Sci; 2022 Jan; 27(1):222-228. PubMed ID: 33384219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.
    De Sanctis R; Agostinetto E; Masci G; Ferraro E; Losurdo A; Viganò A; Antunovic L; Zuradelli M; Torrisi RMC; Santoro A
    Oncology; 2018; 94 Suppl 1(Suppl 1):19-28. PubMed ID: 30036884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment Out Come of Eribulin in Patients with Advanced or Metastatic Breast Cancer Who Resistant to Anthracycline and Taxane].
    Tanaka N; Ogura K; Hattori A; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Naritaka Y; Hirano A
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1200-1202. PubMed ID: 29394580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.
    Patel DA; Xi J; Luo J; Hassan B; Thomas S; Ma CX; Campian JL
    Breast Cancer Res Treat; 2019 Apr; 174(2):443-452. PubMed ID: 30604000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer.
    Ito M; Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Saito M
    Med Oncol; 2019 Sep; 36(10):89. PubMed ID: 31520329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment.
    Kashiwagi S; Tsujio G; Asano Y; Goto W; Takada K; Takahashi K; Morisaki T; Fujita H; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    J Transl Med; 2018 Mar; 16(1):54. PubMed ID: 29523158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
    Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
    BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
    Kashiwagi S; Fukushima W; Asano Y; Goto W; Takada K; Noda S; Takashima T; Onoda N; Ohsawa M; Hirakawa K; Ohira M
    BMC Cancer; 2017 Aug; 17(1):604. PubMed ID: 28859615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis.
    O'Shaughnessy J; Cortes J; Twelves C; Goldstein LJ; Alexis K; Xie R; Barrios C; Ueno T
    Sci Rep; 2020 Jul; 10(1):11203. PubMed ID: 32641747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
    Iwasa T; Tsurutani J; Watanabe S; Kato R; Mizuno Y; Kojima Y; Takashima T; Matsunami N; Morimoto T; Yamamura J; Ohtani S; Tanabe Y; Yoshinami T; Takano T; Komoike Y; Nakagawa K
    BMC Cancer; 2019 Oct; 19(1):962. PubMed ID: 31619197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive prognostic prediction of metastatic breast cancer treated with eribulin using blood‑based parameters and ratio.
    Shimada H; Fujimoto A; Matsuura K; Kohyama S; Nukui A; Ichinose Y; Asano A; Ohara M; Ishiguro H; Osaki A; Saeki T
    Mol Clin Oncol; 2024 Feb; 20(2):15. PubMed ID: 38274088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab.
    Hong J; Chen X; Gao W; Zhu S; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Fei X; Lin L; Shen K
    Cancer Manag Res; 2019; 11():3371-3379. PubMed ID: 31114373
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
    Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
    BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
    Schwartzberg L; McIntyre K; Wilks S; Puhalla S; O'Shaughnessy J; Berrak E; He Y; Vahdat L
    BMC Cancer; 2019 Jun; 19(1):578. PubMed ID: 31195996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry.
    Pouwels XGLV; Ramaekers BLT; Geurts SME; Erdkamp F; Vriens BEPJ; Aaldering KNA; van de Wouw AJ; Dercksen MW; Smilde TJ; Peters NAJB; van Riel JMGH; Pepels MJ; Heijnen-Mommers J; Tjan-Heijnen VCG; de Boer M; Joore MA
    Acta Oncol; 2020 Sep; 59(9):1123-1130. PubMed ID: 32544366
    [No Abstract]   [Full Text] [Related]  

  • 39. Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study.
    Oruc Z; Kaplan MA; Geredeli C; Yildirim Sari N; Ozaslan E; Aytekin A; Tamer Elkiran E; Koca S; Dogan M; Turan N; Yuce O; Sevinc A; Ercelep O; Isikdogan A
    J BUON; 2020; 25(2):641-647. PubMed ID: 32521847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
    Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
    Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.